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Abstract 
 
Remyelination is a neuroprotective regenerative response to demyelination that restores saltatory 
conduction and decreases the vulnerability of axons to irreversible degeneration. It is a highly 
efficient process: however, as with all regenerative processes, its efficiency declines with ageing. 
Here we argue that this age-related decline in remyelination has a major impact on the natural 
history of multiple sclerosis (MS), a disease often of several decades’ duration. We describe recent 
work on 1) how ageing changes the function of oligodendrocyte progenitor cells (OPC), the cells 
primarily responsible for generating new myelin forming oligodendrocytes in remyelination, 2) how 
these changes are induced by age-related changes in the OPC niche and 3) how these changes can 
be reversed, thereby opening up the possibility of therapeutically maintaining remyelination 
efficiency throughout the disease, preserving axonal health and treating the progressive phase of 
MS. 
 
 
 
Treating progressive MS - a role for remyelination 
 
Since the cause of multiple sclerosis (MS) remains uncertain, the main thrust of MS therapy has been 
to minimise the consequences of the key pathological events [1]. A central objective is to prevent 
axonal loss, which, given that axons do not regenerate in the CNS, will result in cumulative and 
irreversible functional loss. Thus, in the acute lesion occurring in relapsing-remitting (RR) phase of the 
disease, the main aim is to suppress the inflammatory response. Achieving this has been one of the 
great success stories of modern medicine and the advances that have been made in ameliorating the 
RR stage of the disease has witnessed advances as impressive as any in neurology therapy in the last 
20 years. There are now a wide range of highly effective drugs and treatments (including 
hematopoietic stem cell therapy) [2],[3]. However, none of these have significant impact in treating 
the progressive phase of the disease, which remains essentially untreatable. There is therefore an 
urgent medical need to develop effective therapies for progressive MS [4],[5]. 
 
The progressive phase of MS is characterised by neuronal and axonal loss. Some of this may result 
from primary pathology to neurons [6],[7], a possibility that is still not fully resolved, or, as is the case 
in the acute lesion in RR, as a consequence of focal inflammation [8]. However, undoubtedly much of 
it occurs because of disruption of the relationship between the axon and the myelin sheath. One of 
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the key functions of the myelin sheath, in addition to conferring the ability to transmit electrical 
impulses by saltatory conduction, is to preserve the health and integrity of the axon [9]. The evidence 
for this first came from transgenic models in which deletions of gene in oligodendrocytes led to 
secondary degenerative changes in axons [10],[11]. Although not fully understood, the 
oligodendrocyte and the myelin sheath it supports, provides metabolic support for the axon via the 
‘myelinic channels’, cytoplasmic conduits within the compacted myelin sheath [12]. This takes the 
form of delivery of glycolysis products (pyruvate/lactate) via monocarboxylate transporters on the 
oligodendrocyte to underlying axons, which they use for mitochondrial ATP production [13],[14]. 
Thus, in the absence of a myelin sheath, as occurs after demyelination, the exposed axons are 
vulnerable to energy deprivation and liable to undergo degeneration from which it may not recover. 
For this reason, the restoration of new myelin sheaths by remyelination is imperative to preserve 
axonal integrity and thereby prevent the major pathological change underlying the progressive phase 
of the disease [15]. While remyelination occurs as a spontaneous regenerative process early in disease 
it is not a sustained process. The failure of regeneration therefore substantially increases the 
likelihood of axonal degeneration [16],[17]. 
 
How is remyelination achieved?  
 
When oligodendrocytes are lost, the myelin sheaths become detached from the axon and disintegrate, 
leaving the axon intact. This is the process of demyelination and is a prominent feature of the complex 
pathology of MS. The default response to demyelination is the spontaneous regenerative process of 
remyelination, in which new myelin sheath-forming oligodendrocytes are generated [18]. The new 
oligodendrocytes come from an abundant and widespread population of multipotent adult CNS 
progenitors, called oligodendrocyte progenitors or OPCs. In response to injury, the OPCs become 
activated (a specific change in their gene expression which prepares them for remyelination) [19],[20]; 
migrate and divide, so that they become abundant within the area of demyelination[21]; and finally 
differentiate into mature oligodendrocytes that wrap the exposed axons with new myelin sheaths. 
[22]-[24]. Although oligodendrocytes do not generate new oligodendrocytes, [25] it is possible that 
remyelination may also occur as a result of surviving oligodendrocytes establishing new myelin 
internodes[26],[27], although the evidence for this in MS is complicated by difficulties in 
unambiguously identifying areas of remyelination. Remyelination is a true regenerative process that 
not only restores the tissue to its pre-lesion architecture, but also restores saltatory conduction and 
supports axon survival [28],[29]. 
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Why does remyelination fail in MS?  
 
Although remyelination can be efficient and widespread in MS it is not sustained throughout the 
disease [30]. There have been many reasons put forward to explain failure of remyelination in MS 
[18],[31]. Our contention is that one of the primary and overarching reasons is ageing.  
 
As with all other regenerative processes in mammals, the efficiency of remyelination declines during 
adulthood [32],[33]. This has been demonstrated experimentally as the time it takes for remyelination 
to be completed taking progressively longer with increasing age [34]. With ageing, each step of 
remyelination becomes slower [35]. The last phase in which recruited progenitors differentiate is rate 
limiting, since increasing OPC provision after demyelination in aged animals does not increase the 
efficiency of remyelination [36],[37].  
 
Why is the age-dependent decline in remyelination important in multiple sclerosis?  
 
MS is a chronic demyelinating disease, with episodes of focal inflammation and demyelination 
occurring at intervals throughout the disease, although becoming less frequent with time [1]. It often 
starts in young adults in their earlier 20s (although can be much younger), while the age expectancy 
is only reduced by a few years [38]. So, many individuals affected by MS may have the disease for 
several decades, and meaning that simply by virtue of growing older the ability to remyelinate areas 
of demyelination declines.  An important consequence of this is that demyelinated axons will remain 
exposed for longer periods and are therefore more vulnerable to irreversible degeneration, a 
consequence compounded by the likely age-related increase in axonal vulnerability [39].  There is 
substantial evidence to support the hypothesis that the age-related failure of remyelination plays a 
prominent role in the transition from RR disease into progressive disease, characterised by progressive 
neuronal atrophy and axonal loss. First, a prediction of this hypothesis is that the transition from RR 
to progressive should occur at around the same age regardless of age of disease onset - and 
epidemiological evidence exists to support this [40]. Second, since age primarily affects the 
differentiation stage of remyelination then later stages of the disease should be characterized by areas 
of chronic demyelination that contains undifferentiated cells of the oligodendrocyte lineage. Again, 
there is a wealth of pathological data to support this - many (although not all) chronically 
demyelinated lesions contain oligodendrocyte lineage cells that have seemingly failed to differentiate 
in a timely manner [41]-[43]. Third, pathological data indicates that remyelination capacity declines 
with disease chronicity [44]. Fourth, MRI data also supports an age-related decrease in remyelination 
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in MS brains [45].  
 
It follows, therefore, that a logical way of preventing the irreversible axonal loss attributable to age-
related remyelination failure is to provide therapies that promote remyelination by rejuvenating 
endogenous OPCs and their environment. This would provide a treatment for the currently 
untreatable progressive phase of the disease, for which there is a universally acknowledged urgent 
medical need [46]. 
 
What changes occur with ageing that lead to a decline in remyelination efficiency?  
Remyelination is ultimately mediated by adult OPCs as they differentiate into new oligodendrocytes. 
However, there are many cell types present within lesions that contribute to creating an environment 
conducive to remyelination, including activated astrocytes [47]-[49], electrically active axons [50], 
pericytes [51], adaptive immune cells (regulatory T cells) [52] and innate immune cells 
(macrophages/microglia) [53]-[55]. Thus, age effects can be divided into those that are cell 
autonomous changes in aging OPC or non-cell autonomous changes that occur in cell types indirectly 
involved in the formation of new oligodendrocytes. Of the non-cell autonomous age-effects, those on 
macrophages and microglia, important in remyelination for producing pro-remyelination factors and 
removing by phagocytosis myelin debris which contains inhibitors of differentiation, have been the 
most extensively studied. With age, these cells become less efficient at removing and processing 
myelin debris and alter their gene expression profiles [56]-[60]. Astrocytes, which play key roles in 
remyelination, also change with ageing [61], and it is likely that these changes impact of their ability 
to support remyelination, although this has not yet been extensively studied. 
 
The ageing-induced decline in OPC function  
 
In order to gain a better understating of why remyelination declines cell autonomous changes in OPCs 
with ageing we have developed protocols for isolating OPCs from different aged adult rodent [62]. 
This has been a significant breakthrough in understanding the limitations on remyelination since 
culturing OPCs from aged adult rodents has hitherto proven to be a major technical obstacle. First, we 
found that while OPCs derived from young adult rats (2-3 months of age - henceforth called young 
adult OPCs) will differentiate into oligodendrocytes in media commonly used for differentiation, OPCs 
from aged adult rodents (>12 months - now referred to as aged adult OPCs) hardly differentiate at all. 
Moreover, while young adult OPCs differentiation can be enhanced using thyroid hormone and 
several other factors that induce differentiation, two of which, benzatropine [63],[64] and 9cis retinoic 
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acid [65], are the basis of current remyelination-enhancing clinical trials, these factors fail to induce 
differentiation in aged adult OPCs. Thus, there is a central dilemma in remyelination therapies: as 
remyelination efficiency declines and the need for remyelination therapies increases, adult OPCs 
become increasingly less responsive to pro-differentiation agents.  
 
OPC ageing and the role of mechanosensing 
 
Although adult OPC undergo functional decline with ageing, it was not known whether this is due to 
intrinsic, cell-autonomous ageing, or whether it is due to extrinsic factors such as age-related changes 
in the OPC niche. To test this, we transplanted aged OPCs, which in their normal environment rarely 
undergo division, into the neonatal CNS, and found that they proliferated to the same extent as the 
endogenous neonatal OPCs [66]. Conversely, young OPCs transplanted into the aged brain cease 
proliferating. This result strongly suggested that the age-associated changes in OPC function were of 
extrinsic rather than intrinsic origin. To confirm this, we made substrates from de-cellularised brains 
from young and aged CNS and seeded on to these OPCs derived from young or old brain. The OPCs 
acquired the function and age-related transcriptome of the age of the substrate rather than their age 
of origin. We found, using atomic force microscopy, that a key change in the ageing brain is its 
increasing stiffness. Since OPC are known to be mechanosensitive, we tested whether this change was 
related to OPC aging by repeating the experiment using chemically inert acrylamide gels, tuned to the 
stiffness of young or aged brain, and found the same effect. We further went on to show that this 
stiffness induced age-setting of adult OPC is mediated by the mechanosensing ion channel, Piezo 1.  
 
Can the effects of ageing on remyelination be reversed? 
 
Crucial to the success of myelin regenerative therapies as patients age is the question of whether the 
effects of ageing are reversible. We established that this can be done in a proof-of-principle 
experiment in 2012 using the model of heterochronic parabiosis, in which lesions in old mice were 
bathed in factors and cells from young mice [56]. This resulted in significantly improved remyelination 
in the aged animals, in part due to the re-modelling of the lesion environment by monocytes derived 
from the young parabiotic partner. We also showed that remyelination in aged rats could be improved 
using a single molecule - the RXRγ agonist 9cis retinoic acid [65]. We have now generated RNASeq 
transcriptomic profiles of young and old adult OPCs, which has enabled us to understand better the 
intrinsic changes occurring in OPCs as they age [62]. Several pathways change with ageing, including 
pathways associated with nutrient signaling, which prompted us to examine the effects of calorie 
 7 
restriction (CR) by intermittent fasting, a well-established modulator of ageing, on remyelination in 
aged animals. We found that fasting had a profound effect, enabling aged animals to remyelinate with 
the efficiency of young adults. Most intriguingly, we found that this rejuvenation of remyelination can 
be phenocopied with the AMPK agonist and widely prescribed drug, metformin. Moreover, metformin 
is able to ‘recalibrate’ aged OPCs, reversing the hallmarks of ageing and rendering them responsive to 
pro-differentiation factors. These results have profound implications for the development of myelin 
regenerative therapies. They mean that, in combination with metformin, pro-differentiation drugs 
might now be effective in aging patients in most need of myelin regenerative therapies.  
 
In our studies on the role of mechanosensing by aged OPCs, we found that deleting Piezo 1 in vitro 
and in vivo (using a novel OPC-specific CRISPR-based gene editing approach delivered systemically 
using AVV) causes aged OPCs to function as if they were young adult OPCs, and providing further 
evidence that aged OPCs can be rejuvenated and contribute to efficient remyelination [66]. An 
interesting but as yet unanswered question is whether CR or CR-mimetics exert their effect, at least 
in part, by changing the stiffness of the ageing brain. Thus, recent work from our own and other 
laboratories have made ground-breaking strides in understanding the nature and importance of the 
age-related decline in remyelination and how, potentially, these may be reversed in a therapeutically 
meaningful manner (Fig. 1). 
 
Conclusions 
 
Remyelination is a spontaneous regenerative process that naturally follows demyelination. However, 
as with all regenerative processes in mammals, its efficiency declines with ageing, a phenomenon 
central to the aging process itself.  This generic feature of the biology of regeneration has important 
implications for MS, a chronic disease often of several decades’ duration.  As an individual progresses 
through adult life with the disease their ability to replace lost myelin sheaths decreases, eventually 
reaching a point where myelin regeneration is too slow to prevent axonal degeneration, and the 
disease enters the currently untreatable progressive phase. In this article we argue that a potent way 
to address the disease progression is to develop therapies that sustain remyelination throughout adult 
life, and reverse the effects of ageing. Central to this goal is to understand the consequences of ageing 
for the biology of the OPCs. We have shown that the adult OPC acquires all the predictable hallmarks 
of adult stem cell ageing, which collectively contribute to its declining function and ability to generate 
new oligodendrocytes during remyelination. The age-associated decline in function is not due to 
intrinsic cell ageing but rather is the result of extrinsic changes in the OPC niche and specifically an 
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increase in tissue stiffness. The implications of this is that the age-effects on OPC are not ‘cast in stone’ 
and that given the correct signals the aged OPC can be reverted to a ‘young’ OPC capable of effective 
remyelination (Fig. 1). This fundamental concept offers enormous hope for the prospects of 
developing remyelination therapies that will be effective throughout the duration of the disease and 
that will combat the challenges of treating progressive MS. 
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Figure legend 
 
Figure 1. OPCs, like other adult stem cells, undergo functional decline with ageing:  they have a 
diminished ability to self-renew and to differentiate. The dysfunction of aged OPCs is underlined by 
the acquisition of hallmarks of ageing, like DNA damage and mitochondrial dysfunction. The functional 
capacity of an OPC is determined by its environment (niche) as OPCs transplanted, irrespective of their 
own age, function like OPCs of the age of the host tissue (i.e. young or aged OPCs transplanted into a 
young brain behave like young OPCs). Many biochemical and histological changes that occur in the 
extracellular environment with ageing have been described but our recent data demonstrates that 
the physical properties (stiffness) of the brain play a key role in the ageing process. Interventions, such 
as heterochronic parabiosis or treatment with metformin restores a youthful niche and can reinstate 
the stem cell potential of OPCs and thereby their capacity for remyelination. Alternatively, aged OPCs 
can be reprogrammed to a more youthful state. The deletion Piezo1 prevents OPCs from sensing the 
stiffness of the niche.  Thus, aged OPCs behave as young OPCs that are normally exposed to a soft 
environment. Therefore, strategies that restore a more youthful environment or that make OPCs 
impervious to extracellular changes that occur with ageing lead to a functional rejuvenation of OPCs 
and thereby store the capacity of aged animals for remyelination.  
 
 
